Xalud Therapeutics, Inc.

Scrip asked 30 industry leaders to share their thoughts around what the biopharma industry will do – and what it needs to do – to advance diversity, equity and inclusion (DEI) this year. Their respon

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com

The amount of venture capital raised during the second quarter of 2021 was almost double the total raised in the second quarter of 2020, but the biggest reason that biopharma financings jumped from $3